401 related articles for article (PubMed ID: 28439109)
1. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
Hari P; Mateos MV; Abonour R; Knop S; Bensinger W; Ludwig H; Song K; Hajek R; Moreau P; Siegel DS; Feng S; Obreja M; Aggarwal SK; Iskander K; Goldschmidt H
Leukemia; 2017 Dec; 31(12):2630-2641. PubMed ID: 28439109
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.
Weisel K; Mateos MV; Gay F; Delforge M; Cook G; Szabo Z; Desgraz R; DeCosta L; Moreau P
Leukemia; 2021 Jun; 35(6):1732-1744. PubMed ID: 33067574
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma.
Facon T; Niesvizky R; Mateos MV; Siegel D; Rosenbaum C; Bringhen S; Weisel K; Ho PJ; Ludwig H; Kumar S; Wang K; Obreja M; Yang Z; Klippel Z; Mezzi K; Goldrick A; Tekle C; Dimopoulos MA
Blood Adv; 2020 Nov; 4(21):5449-5459. PubMed ID: 33166401
[TBL] [Abstract][Full Text] [Related]
11. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Goldschmidt H; Moreau P; Ludwig H; Niesvizky R; Chng WJ; Joshua D; Weisel K; Spencer A; Orlowski RZ; Feng S; Iskander KS; Dimopoulos MA
Leuk Lymphoma; 2018 Jun; 59(6):1364-1374. PubMed ID: 28937327
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
Gregersen H; Peceliunas V; Remes K; Schjesvold F; Abildgaard N; Nahi H; Andersen NF; Vangsted AJ; Klausen TW; Helleberg C; Carlson K; Frølund UC; Axelsson P; Stromberg O; Blimark CH; Crafoord J; Tsykunova G; Eshoj HR; Waage A; Hansson M; Gulbrandsen N
Eur J Haematol; 2022 Jan; 108(1):34-44. PubMed ID: 34536308
[TBL] [Abstract][Full Text] [Related]
14. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
Dimopoulos MA; Moreau P; Iida S; Huang SY; Takezako N; Chng WJ; Zahlten-Kumeli A; Sersch MA; Li J; Huang M; Lee JH
Int J Hematol; 2019 Oct; 110(4):466-473. PubMed ID: 31388932
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
Moreau P; Joshua D; Chng WJ; Palumbo A; Goldschmidt H; Hájek R; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Aggarwal S; Feng S; Dimopoulos MA
Leukemia; 2017 Jan; 31(1):115-122. PubMed ID: 27491641
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Palumbo A; Obreja M; Aggarwal S; Moreau P
Br J Haematol; 2017 May; 177(3):404-413. PubMed ID: 28211560
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson GH; Pawlyn C; Cairns DA; de Tute RM; Hockaday A; Collett C; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Rocci A; Snowden JA; Jenner MW; Cook G; Russell NH; Drayson MT; Gregory WM; Kaiser MF; Owen RG; Davies FE; Morgan GJ;
PLoS Med; 2021 Jan; 18(1):e1003454. PubMed ID: 33428632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
